摘要
咪达普利不仅具有良好的降压效果 ,而且不良反应小 ,患者依从性好 ,作为新的血管紧张素转化酶抑制剂体现出不同于其它同类药物及肾上腺素能受体结合剂制剂的优越性 ,在心血管疾病治疗中具有广泛的应用前景。
Imidapril is not only effective on reducing blood pressure,but also well tolerated.As a new ACE inhibitor,imidapril provides an effective alternative and significant clinical advantage to other ACE inhibitors and ARBs,which can support special application in cardiovascular disease.
出处
《心血管病学进展》
CAS
2005年第1期21-23,共3页
Advances in Cardiovascular Diseases